Drug Shortage Report for AMIKACIN SULFATE INJECTION USP
Report ID | 203649 |
Drug Identification Number | 02242971 |
Brand name | AMIKACIN SULFATE INJECTION USP |
Common or Proper name | AMIKACIN |
Company Name | SANDOZ CANADA INCORPORATED |
Market Status | MARKETED |
Active Ingredient(s) | AMIKACIN |
Strength(s) | 250MG |
Dosage form(s) | LIQUID |
Route of administration | INTRAVENOUS INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR |
Packaging size | 2ML |
ATC code | J01GB |
ATC description | AMINOGLYCOSIDE ANTIBACTERIALS |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | |
Actual start date | 2023-09-05 |
Estimated end date | 2023-09-29 |
Actual end date | 2023-10-02 |
Shortage status | Resolved |
Updated date | 2023-10-03 |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 110 RUE DE LAUZON BOUCHERVILLE, QUEBEC CANADA J4B 1E6 |
Company contact information | 1 800-361-3062 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v1 | 2023-09-05 | English | Compare |
v2 | 2023-09-05 | English | Compare |
v3 | 2023-09-05 | French | Compare |
v4 | 2023-09-06 | English | Compare |
v5 | 2023-10-02 | English | Compare |
v6 | 2023-10-02 | French | Compare |
v7 | 2023-10-03 | English | Compare |
Showing 1 to 7 of 7